92-55-7 + 5351-23-5 = 965-52-6 反应条件:1.1 Solvents: N-Methyl-2-Pyrrolidone; Rt -> 100 °C; 3.5 H,100 °C 标题:The Research On The Synthesis Of 4-Hydroxy-N'-((5-Introfuran-2-Yl)Methylene) Benzohydrazide 作者:Zhang,Shuai; Li,Dian-Qing; Shi,Zhi-Qiang 参考文献:Shandong Huagong 日期:2010 卷标:39(4) 页码:1-2]
5351-23-5 + 698-63-5 = 965-52-6 反应条件:1.1 Catalysts: Acetic Acid Solvents: Water; 5 Min,Rt1.2 Rt; 30 Min,Rt 标题:Nitrofuran Drugs Beyond Redox Cycling: Evidence Of Nitroreduction-Independent Cytotoxicity Mechanism 作者:Gallardo-Garrido,C.; Cho,Y.; Cortes-Rios,J.; Vasquez,D.; Pessoa-Mahana,C. D.; Et Al 参考文献:Toxicology And Applied Pharmacology 日期:2020 卷标:401]
= 965-52-6 [标题:Reaction Conditions 标题:Synthesis And Antimicrobial Activity Of New Furan Derivatives 作者:El-Obeid,Humeida A.; Elnima,Elamin I.; Al-Badr,Abdullah A. 参考文献:Pharmaceutical Research 日期:1985 卷标:(1) 页码:42-3]
5351-23-5 + 698-63-5 = 965-52-6 反应条件:1.1 Catalysts: Sulfuric Acid Solvents: Tetrahydrofuran,Water 标题:Kinetics And Mechanism Of Schiff Base Formation From 5-Nitro-2-Furaldehyde. Part Iii. Nifuroxazide 作者:Jovanovic,Slobodanka; Misic-Vukovic,Milica; Popovic,Spasenija; Dumanovic,Dragica; Dokovic,Dejan 参考文献:Journal Of The Serbian Chemical Society 日期:1987 卷标:52(5) 页码:245-53]
= 965-52-6 [标题:Reaction Conditions 标题:Preparation Of New Crystalline Forms Of 4-Hydroxy-N'-[(5-Nitrofuran-2-Yl)Methylene]Benzohydrazide 参考文献:Romania]
对羟基苯甲酰氯置于hydrazine Hydrate体系中,用 乙醇 作为反应溶剂,化学反应 2.5H,反应生成 硝呋酚酰肼 参考文献:Synthesis And Investigation Of Antimicrobial Activity Of Some Nifuroxazide Analogues 标题:Synthesis And Investigation Of Antimicrobial Activity Of Some Nifuroxazide Analogues 摘要:一系列硝呋醛酰肼类衍生物[(2A-2E)-(10A-10F)]已被合成,结构鉴定,并测试了其对一组细菌(革兰氏阳性和革兰氏阴性)和类酵母致病真菌白色念珠菌的抗微生物活性.在这一系列化合物中,活性最高的为4-氨基苯甲酸(5-硝基呋喃-2-亚甲基)酰肼(2B)和2-氨基苯甲酸(5-硝基呋喃-2-亚甲基)酰肼(2D).此外,化合物(9A-9G)和(10A-10G)对选定物种无活性,除了化合物(9F)和(10F),这表明使用呋喃酰肼及其对应的噻吩酰肼并未提高此类化合物的抗菌活性.对于对白色念珠菌的活性,所有化合物均无活性,除了取代的硝基呋喃(2A-2D). DOI:10.14233/ajchem.2015.18896
专利号:WO-2022146324-A1 优先权日:2020-12-29 标 题 :Synthesis of pyrimidine-4(lh)-one derivatives from new hydrazineylidene 发明人:SARIPINAR EMIN; BURCU HILAL JANSET; KEKEÇMUHAMMED HÜSEYIN; TAPERA MICHAEL 权利人:T C ERCIYES UENIVERSITESI 摘要:This invention relates to the synthesis of pyrimidine-4 (1H)-one derivatives from Meldrum's acid, carbonyl compounds (aldehyde/ketone), and guanylhydrazone derivatives and tautomers, enantiomers, and salts thereof.
专利号:WO-2025085030-A1 优先权日:2023-10-18 标 题:Synthesis of semisynthetic penicillin derivatives containing hydrazone-derived thiazolidine and imidazole ring 发明人:SARIPINAR EMIN; BURAN SUMEYYE 权利人:ERCIYES UNIV 摘要:The present invention relates to the novel semi-synthetic thiazolidine and imidazole penicillin, pharmaceutically acceptable derivatives thereof and their synthesis method that may cause biologically significant changes by the N-acylation reaction of 6-aminopenicillanic (6-APA) using new trisubstituted thiazolidine and imidazole acetyl chloride derivatives. The invention also relates to pharmaceutical compositions comprising these compounds and their use for therapeutic treatment in the human or animal body.
专利号:WO-2025085026-A1 优先权日:2023-10-18 标 题:Synthesis of semisynthetic penicillin derivatives containing hydrazone-derived thiazolidine and imidazole ring 发明人:SARIPINAR EMIN; BURAN SUMEYYE 权利人:T C ERCIYES UNIV 摘要:The present invention relates to the novel semi-synthetic thiazolidine and imidazole penicillin, pharmaceutically acceptable derivatives thereof and their synthesis method that may cause biologically significant changes by the N-acylation reaction of 6-aminopenicillanic (6-APA) using new trisubstituted thiazolidine and imidazole acetyl chloride derivatives. The invention also relates to pharmaceutical compositions comprising these compounds and their use for therapeutic treatment in the human or animal body.
专利号:US-2024336679-A1 优先权日:2021-08-06 标题 :Methods for the treatment of cancer 发明人:LINARES LÆTITIA; FIRMIN NELLY; MANTEAUX GABRIELLE 权利人:INST REGIONAL CANCER MONTPELLIER; INST NAT SANTE RECH MED; UNIV MONTPELLIER 摘要:The present disclosure relates to an Interleukin-6 (IL-6) signaling inhibitor selected from an IL-6 inhibitor, an IL-6 receptor inhibitor, an IL-6/IL-6 receptor complex inhibitor, a gp130 inhibitor and a STAT3 inhibitor or a pharmaceutical composition comprising such an IL-6 signaling inhibitor. for use in a method for treating and/or preventing cancer in a subject in need thereof. wherein the subject has been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin. The inventors have observed that cancers exhibiting recruitment of MDM2 to chromatin have been shown to secrete IL-6 that in turn acts on myoblast cells to activate serine synthesis. Following these surprising and unexpected observations. the inventors set up methods of treatment that are able to induce cancer cells death in subjects that have been previously classified as being affected with a cancer exhibiting recruitment of MDM2 to chromatin.
专利号:US-2007021349-A1 优先权日:2005-04-28 标题:Orthogonally protected bifunctional amino acid 发明人:SRINIVASAN ANANTH; LUYT LEONARD G 权利人:SRINIVASAN ANANTH; LUYT LEONARD G 摘要:The present invention concerns novel orthogonally protected amino acids, there production and use for the synthesis of binding compounds usable in the diagnosis and treatment of proliferative diseases, in particular tumor diseases.
专利号:US-4093812-A 优先权日:1975-03-25 标 题:(Nitrofuryl)pyrazoles, their synthesis and use, and compositions containing them 发明人:RAINER GEORG 权利人:BYK GULDEN LOMBERG CHEM FAB 摘要:3-(5-Nitro-2-furyl)pyrazoles unsubstituted in the 5-position and 5-(5-nitro-2-furyl)pyrazoles unsubstituted in the 3-position are antimicrobials and disinfectants. The compounds are structurally represented by one of the formulae: ##STR1## wherein A is --CHO, --CN, --COOH, a protected or derived aldehyde group or a protected or derived carboxylic acid group; n B is 5-nitro-2-furyl; n R 1 is --H, substituted or unsubstituted hydrocarbyl (saturated or unsaturated; acyclic, alicyclic or aromatic; or araliphatic); substituted or unsubstituted (cycloaliphatic or aromatic) heterocyclic or acyl (carboxylic or carbonic acid); n R 2 is --H; and n n is a positive whole number of at most 2.
1: Hofnung M, Quillardet P, Michel V, Touati E. Genotoxicity of 2-nitro-7-methoxy-naphtho[2,1-b]furan (R7000): a case study with some considerations on nitrofurantoin and nifuroxazide. Res Microbiol. 2002 Sep;153(7):427-34. Review. Review.
合成参考文献
摘要:S109 | PARCEDC | List of 7074 potential endocrine disrupting compounds (EDCs) by PARC T4.2 | DOI:10.5281/zenodo.10944198 摘要:S72 | NTUPHTW | Pharmaceutically Active Substances from National Taiwan University | DOI:10.5281/zenodo.3955664 摘要:S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (2021) DOI:10.1021/acsenvironau.1c00008. List downloaded from 摘要:Nifuroxazide: licence modification. New restrictions in children. Prescrire Int. 2004 Apr;13(70):53. 参考文献:10.1248/cpb.54.807 摘要:Ayad MM, Youssef NF, Abdellatif HE, Soliman SM. A comparative study on various spectrometries with thin layer chromatography for simultaneous analysis of drotaverine and nifuroxazide in capsules. Chem Pharm Bull (Tokyo). 2006 Jun;54(6):807–13. doi: 10.1248/cpb.54.807.